Effect of Uroacitides for cholangiocarcinoma treated by interventional therapy

Effect of Uroacitides for cholangiocarcinoma treated by interventional therapy-a RCT

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000066

Enrollment

Unknown

Registered

2008-03-04

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mid-advanced cholangiocarcinoma

Interventions

Group A:Uroacitides is administrated after the intervention operation for a week (200 ml per day). Then 5-Fu (200mg/m2) and DDP (10mg/m2) is intravenous used for a week.

Group B:5-Fu (200mg/m2) and DDP (10mg/m2) is intravenous administrated for a week After Intervention operation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Stage III, IV cholangiocarcinoma confirmed by pathology; 2. There is at least 1 lesion whose bi-diameter can be measured (diameter>1cm) in imageology; 3. KPS scale =70; 4. Aged 18-80 years old; 5. Expectant survival 3>months; 6. Having good compliance in follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with history of using Uroacitides; 2. Patients with other carcinoma; 3. With uncontrolled infection; 4. Main organ dysfunction; 5. Pregnant or lactated women; 6. Patients with psychiatric disease history.

Design outcomes

Primary

Measure	Time frame
Survival rate;Tumor improvement;	—

Secondary

Measure	Time frame
Tumor marker;Symptom improvement;Adverse reaction;Weight Change;Laboratory outcome measurement;	—

Countries

China

Contacts

Public ContactXinwei Han

lzjrfs@sina.com+86 0 13803842129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026